Scaling Liquid Biopsy Innovation Across the Middle East with MSK-ACCESS™ powered with SOPHiA DDM™

From genomic innovation to real-world implementation: exploring the future of liquid biopsy and precision oncology across the Middle East.

The conversation around precision medicine is rapidly evolving. In this on-demand session, leading oncology experts, healthcare decision-makers, pharmaceutical partners, policy representatives, and key opinion leaders come together to explore how liquid biopsy is transforming cancer care delivery and genomic testing strategies across the region.

Watch the full recording to hear expert perspectives, real-world experiences, and practical insights from leading institutions.

What You'll Discover

This high-level discussion explores the evolving role of liquid biopsy in precision oncology and the opportunities to bring advanced genomic testing closer to patients.

Decentralizing precision oncology
Learn how Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS collaborated to decentralize MSK’s renowned genomic assay, MSK-ACCESS™, powered with SOPHiA DDM™ for liquid biopsy applications.

From innovation to implementation
Hear real-world perspectives on implementing advanced genomic testing and scaling precision oncology solutions in clinical practice.

Regional insights from the Middle East
Discover how healthcare leaders in the region are approaching innovation, scalability, and the integration of genomic testing into cancer care.

The evolving role of liquid biopsy
Explore how liquid biopsy can contribute to more accessible and actionable genomic testing strategies and support the continued evolution of precision medicine.

Watch the Expert Discussion

Featuring perspectives from leading oncology, genomics, and precision medicine experts from Memorial Sloan Kettering Cancer Center, M42, and SOPHiA GENETICS.

Register Now

Company

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Organization(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services